Drug Trial Radar · NCT06783829
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jan 22, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
Conditions
- Prostate Cancer
Interventions
SHR4394Drug
SHR4394
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: 3 weeks.
- Maximal tolerable dose (MTD)Time frame: 3 weeks.
- Adverse events (AEs)Time frame: Screening up to study completion, an average of 1 year.
- Recommended phase II dose (RP2D)Time frame: Screening up to study completion, an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.